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SUMMARY
Objective: To investigate factors determining changes in initial antiretroviral therapy 
(ART) in patients attended to in an AIDS tertiary care hospital in Ceará, Brazil. Meth-
ods: This descriptive and exploratory study used the analysis of request to initiate or 
change treatment forms in the year of 2008, and the changes in therapy were followed 
through the first year of treatment. Data were analyzed with SPSS and EpiInfo by using 
ANOVA and the exact test of the coefficient of contingency, with significance at p < 0.05. 
Results: From 301 patients initiating ART, 22.1% (n = 68) needed a change in the first 
year. These patients were mostly males, aged 20 to 39 years; with only one ART changed 
needed in 86.8% of the cases (n = 59). Reports of two or three changes in regimen were 
observed. Zidovudine was the drug most often changed, followed by lopinavir/ritonavir 
and efavirenz. A significant association was found between changes in initial regimens 
and the report of adverse reactions (p < 0.001). Conclusion: The main factor determin-
ing changes in the initial ART was an adverse reaction report. Most patients had one 
change in the initial ART over the first year of treatment. ART monitoring contributed 
to a better control of the specific drug therapy.
Keywords: Acquired immunodeficiency syndrome; highly active antiretroviral therapy; 
drug toxicity.
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INTRODUCTION
AIDS, for its pandemic character, represents one of the 
greatest current public health problems. In Brazil, ap-
proximately 506,000  cases were reported as of 20081. In 
the state of Ceará, 254 deaths from AIDS were reported in 
2007, and 945 new cases of the disease were reported in 
20082. These data may be related to the policy of access to 
antiretroviral treatment and to early diagnosis1,2.
Since 1996, through the Law 9313, the Ministry of 
Health (Ministério da Saúde – MS) has ensured free ac-
cess to antiretroviral therapy to all HIV carriers, thus pro-
moting a positive impact and a noticeable improvement 
in morbidity, mortality, and quality of life indicators3.
The study was conducted in a HIV-AIDS tertiary 
care hospital in Ceará, which currently attends to 2,600 
patients (adults, pregnant women, and children) receiv-
ing antiretroviral therapy (ART). Among these patients, 
the number of those who need a rescue therapy is large 
because they have often used several treatment regimens 
and had more than one therapy failure in prior trials. 
Thus, the hospital sta has members of the Interinstitu-
tional Committee of Antiretroviral Therapy (Comissão 
Interinstitucional de Terapêutica Antirretroviral – CITA), 
which regulates the changes in patients’ therapies and su-
pervises these interventions based on specific forms and 
on data endorsed by the MS.
Consensus recommendations for the chosen rescue 
therapy are few, due to the small number of clinical tri-
als comparing dierent strategies. The majority of current 
studies provide data about experience in rescue therapy 
focusing on new drugs. In addition, the heterogeneity of 
patients presenting therapy failure does not allow for the 
adoption of an absolute rule3.
With the increasing number of patients on ART, treat-
ment monitoring from its onset has become a priority in 
public health. Rescue therapy not only has an elevated 
cost, but non-adherence can result in mutations and resis-
tant virus selection, which justifies the need for follow-up 
for these patients4.
In the United States and in Europe, the average time 
the patient uses the initial ART is lower than one year 
and, although data are not numerous, this time seems to 
be considerably higher in Brazil and in other developing 
countries5.
Better understanding of the factors associated with the 
initial ART change, of the documentation of the informa-
tion regarding the patient and the pharmacotherapy in 
the proposed change is important for managing patients 
in the drug context. Thus, the current study aimed to de-
scribe and analyze changes in the initial ART in patients 
attended to in our hospital, so that a basis for treatment 
quality, safety, and eectiveness can be provided, as well 
as for judicious use of these drugs.
METHODS
This descriptive, exploratory, retrospective, and documen-
tation-based study was performed in the pharmacy service 
of an infectious disease-specialized tertiary care hospital of 
the Department of Health of the State of Ceará. The Request 
Forms for Initial Treatment or Treatment Change of all out-
patients initiating antiretroviral therapy in the year 2008 
and whose medication had been changed over the first year 
of treatment were sequentially analyzed. Thus, the patients 
were followed-up for one year after treatment initiation and, 
therefore, had their data acquired until the year 2009.
From 301 patients investigated, 68 had an ART change 
request and, among these, some had more than one change 
request, resulting in the generation of 78 forms. These forms 
prepared by CITA were filled by the physician attending to 
the patient on ART and submitted to the committee through 
the facility’s pharmacy service. After being analyzed, the 
forms were sent back to the pharmacy in order to enable 
dispensation, and the forms were archived for five years. 
The request form contained items regarding the patient 
identification, symptom presence or absence, treatment na-
ïve status, drugs already used, current drugs, CD4+ T lym-
phocyte count (CD4), viral load (VL), reason for request-
ing a therapy change, new regimen requested, and a field 
for the committee’s opinion about the request. This infor-
mation, obtained from the form during the study period, 
was organized, quantified, and analyzed in a spreadsheet 
containing clinical indicators and variables, such as: age, 
gender, CD4, VL, reason for changing the initial ART, time 
on the same ART regimen, number of favorable and unfa-
vorable CITA opinions regarding the change request, and 
percentage of changes that were in accordance with Brazil-
ian consensus on ART3.
Patients under the age of 18; pregnant women who, in 
some settings, used ART only during the gestational peri-
od; and those who did not stay in the hospital’s outpatient 
follow-up  over the first year of treatment were excluded 
from the study. The results were expressed in tables, in the 
case of qualitative variables, and in central tendency and 
dispersion measures (mean ± standard deviation) in the 
case of quantitative variables. Data were analyzed using the 
Statistical Package for the Social Sciences – SPSS version 
15.0 (SPSS Inc. – Chicago, IL) and EpiInfo version 6.04b 
(Centers for Disease Control and Prevention – Atlanta, 
GA) softwares. The parameters were compared through 
analysis of variance (ANOVA) and the exact test of the 
coefficient of contingency, considering a p-value < 0.05 as 
statistically significant.
The study was designed in accordance to regulatory 
standards and guidelines of research involving humans6, 
ensuring patients’ privacy and data confidentiality. It was 
approved by the hospital’s ethics and research committee 
under the protocol no. 048/2009.
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RESULTS
Over the year 2008, 391 patients were registered into the 
Drug Logistical Control System (Sistema de Controle 
Logístico de Medicamentos – SICLOM) to initiate ART 
at the hospital. 72 patients who did not continue the 
treatment, 16 children, and two pregnant women were 
excluded.
From the 301 patients suitable for analysis, 22.1% 
(n = 68) changed ART over the first year of treatment, 
61,8% (n = 42) of males and 38.2% (n = 26), females, with 
intervals of 49.9-73.6 and 26.4-50.1, respectively, a statis-
tically non-significant dierence in number of changes 
between genders. The predominant age group among 
patients was 20 to 39 years (69.1%; n = 47), followed by 
patients aged 40 to 59 (25%; n = 17) years.
Among the 68 patients experiencing changes in the 
ART regimen in the first year of treatment, 86.8% (n = 59) 
had only one change; 11.8% (n = 8) had two changes, and 
only one patient had three changes, amounting to a total 
of 78 change request forms analyzed.
At the initiation of treatment, 60.3% (n = 41) of pa-
tients were reported as symptomatic, and 16.2% (n = 11) 
as asymptomatic. Some forms did not show information 
about symptomatology (23.5%; n = 16).
The presence of AIDS-related opportunistic diseases 
was reported in the forms of 73.2% (n = 30) of the symp-
tomatic patients, with one occurrence being described in 
63.4% (n = 19), and two occurrences in 3.3% (n = 10) of 
patients. The occurrence of three diseases appeared on 
only one form, and no disease was mentioned in 26.8% 
(n = 11) of the symptomatic patients’ forms. The diseases 
predominantly cited were: neurotoxoplasmosis, candidia-
sis, tuberculosis, histoplasmosis, diarrhea, cytomegalovi-
rus disease, and herpes.
CD4 absolute count was present in 62.7% (n = 52) of 
forms, with results between 2 and 755 cells/mm3. On the 
other hand, VL was present in 60.3% (n = 47), ranging from 
undetectable (< 50 copies/mL) to > 500,000 copies/mL.
In the forms of patients with a CD4 count 
< 500 cells/mm3, the mean VL was 66,314 copies/mL 
(standard error 17,175), and it was higher than the 
VL in patients with a CD4 count > 500 cells/mm3, i.e., 
875 copies/mL (standard error 101), representing a statis-
tically significant result (p = 0.018).
Initial ART regimens using a combination of two 
nucleotide/nucleoside reverse transcriptase inhibitors 
(NRTIs) and one non-nucleoside reverse transcriptase 
inhibitor (NNRTI)  were observed in half of the patients 
(n = 34); the predominant association zidovudine + lami-
vudine (AZT + 3TC) combined with efavirenz (EFV) was 
found in the forms of 54% (n = 27) of patients.
Initial regimens introducing two NRTIs associated 
with one ritonavir (RTV)-boosted protease inhibitor 
(PI) were observed in 44.1% (n = 30) of patients’ forms, 
with the combination AZT+3TC plus lopinavir/ritona-
vir (LPV/r) predominantly used in 70% (n = 21) of pa-
tients’ forms. Other regimens (2 NRTIs + 1 PI, 3 NRTIs 
+ 1 NNRTI, and 2 NRTIs + 2 PIs) were observed in four 
(5.9%) patients.
Among NRTIs, the most often used was 3TC, found 
in 66 (97.1%) regimens, followed by AZT, in 59 (86.8%). 
LPV/r was the most often used PI, present in 22 (62.9%) 
regimens, followed by atazanavir (ATV) boosted by RTV, 
found in 10 (28.5%). The drugs ATV and fosamprenavir 
(FPV) were observed in three (8.6%) regimens. In NNRTI 
class, EFV was the drug most frequently chosen, found in 
30 (85.7%) regimens, followed by nevirapine (NVP), in 
five (14.3%).
Table 1 shows the panel for all the drug changes dur-
ing the study time, including the modifications for the pa-
tients who required more than one ART change over the 
first year of treatment.
The reports of adverse drug reaction (ADR) represent-
ed the main reason for the initial ART change in the ana-
lyzed forms, causing 88.5% (n = 69) of the substitutions, 
followed by five (6.4%) caused by non-adherence to the 
proposed treatment, three (3.8%) modifications caused by 
a report of a rifampin, isoniazid, and pyrazinamide (RIP) 
regimen initiated in patients with tuberculosis, and one 
change aiming to boost the therapeutic regimen already 
selected for the patient. The correlation of main change 
reasons with the drugs changed had a significant value 
(p < 0.0001), as shown in Table 2.
From the 59 patients who initiated ART with AZT, 
42.4% (n = 25) changed to another regimen. Anemia re-
ports occurred from a minimum time of seven days to a 
maximum time of 350 days. From 30 patients initially us-
ing EFV, the drug was changed in 63.3% (n = 19), eight of 
which (42.1%) due to reports of dizziness, insomnia, bad 
dreams, and hallucinations. The reactions occurred over 
periods ranging from 14 to 229 days.
LPV/r was related to a change in 77.3% (n = 17) of 
the 22 initial regimens in which the drugs were used, with 
gastrointestinal reactions being the most frequently cited 
reason for change, presenting from 15 to 154 days.
ATV was related to a change in 3 of the 10 initial 
regimens it was found in, two (66.7%) of them resulting 
from jaundice reports within a minimum of 72 days and 
a maximum of 329 days. Abacavir (ABC) was changed in 
the 4 (5.9%) regimens in which it was initially used: in one 
patient, from a hypersensitivity report, and in the remain-
ing, from drug shortage in dispensation units in the coun-
try. A significant value (p < 0.001) was found when the 
association between the changes to the initial regimens 
was compared with the reported reasons for their occur-
rence, regarding ADR.
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No correlation was found either between the 
drug changed and the opportunistic disease reported 
(p = 0.709), or between the mean time from the treatment 
initiation until the regimen substitution regarding drugs 
(p = 0.688).
From the 78 Request Forms for Initial Treatment 
or Treatment Change analyzed, 89.7% (n = 70) of them 
showed a drug substitution and, in six (7.7%), two drugs 
were substituted. A four-drug substitution was observed 
in one form, and in another one, RTV was requested to 
be added in order to boost the regimen. The substitution 
panel of drugs used in the study first regimens is shown in 
Table 3.
Out of the total of forms (n = 78) submitted to CITA 
approval, 96.2% (n = 75) were directly approved, and in 
3.8% (n = 3) the new proposed regimen was criticized and 
suggestions on a new regimen to be adopted were made, 
based on recommendations endorsed by MS, which were 
posteriorly accepted.
DISCUSSION
There are few studies approaching the problem of ART 
changes over the first year of treatment, which represents 
a limitation to further discussion. Most studies depict 
factors associated with non-adherence as a priority7,8. In 
fact, studies conducted during early ART would be highly 
Initial ART Final ART
Among drugs Percentage 
among 
patients
Among drugs Percentage 
among 
patientsn % n %
AR drugs found in forms
AZT 66 24.4 84.6 43 15.6 55.1
3TC 76 28.0 97.4 78 28.3 100.0
LPV 27 10.0 34.6 22 8.0 28.2
RTV 37 13.7 47.4 42 15.2 53.8
ABC 7 2.6 9.0 11 4.0 14.1
ddl 2 0.7 2.6 4 1.4 5.1
d4T 2 0.7 2.6 2 0.7 2.6
EFV 35 12.9 44.9 28 10.1 35.9
NVP 4 1.5 5.1 4 1.4 5.1
ATV 10 3.7 12.8 23 8.3 29.5
TDF 5 1.8 6.4 19 6.9 24.4
Total 271 100.0 347.4 276 100 352.8
aSource: Request forms for initial therapy or change in antiretroviral therapy (ART) stored in the hospital pharmacy service. AR, antirretroviral; 
AZT, zidovudine; 3TC, lamivudine; LPV, lopinavir; RTV, ritonavir; ABC, abacavir; ddI, didanosine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; 
ATV, atazanavir; TDF, tenofovir.






n % n % n % n %
Drugs changed
AZT 22 100.0 0 0.0 1 5.9 0 0.0
LPV 0 0.0 1 7.1 16 94.1 0 0.0
ABC 0 0.0 1 7.1 0 0.0 0 0.0
EFV 0 0.0 11 78.6 0 0.0 1 50.0
NVP 0 0.0 0 0.0 0 0.0 1 50.0
ATV 0 0.0 1 7.1 0 0.0 0 0.0
Total 22 100 14 100 17 100 2 100
ap-value < 0.0001 with reasons for changes and drugs changed compared in patients initiating antiretroviral therapy in the year 2008. They were 
followed up to 2009. AZT, zidovudine; LPV, lopinavir; ABC, abacavir; ddI, didanosine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; 
TDF, tenofovir.
Table 2 – Correlation between main reasons for change and each drug changeda
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valuable, as the earlier the detection of problems, the lower 
the likelihood of the appearance of a resistant strain and 
other associated problems that make treatment harder9.
In this study, the patients considered on ART were 
only those who continued treatment in the hospital for 
one year, from 2008 to 2009. Those who discontinued were 
excluded, and the reasons for their discontinuation (drop-
out, transfer to another dispenser unit, death, or other rea-
sons) were not investigated.
Over recent years, an increased number of women 
with HIV was observed, due to increased heterosexual 
transmission10. According to the AIDS-STD Epidemiolog-
ical Bulletin, there was a reduction in gender ratio (M:F) 
for AIDS cases, showing a 1.5:1 ratio in 2007, compared to 
6.5:1 in 198811. However, over the year 2008, in the facil-
ity where the study was conducted, the number of male 
patients registered for the initial ART was higher than the 
number of female patients. Despite the data on the in-
creased number of females, this study found values similar 
to a study from Caribbean and Latin America countries, in 
which only 35% of patients were females, with a mean age 
of 37 years12. This study also showed that female patients 
had a higher number of ART changes in the first year of 
treatment12. In the present study, no statistically significant 
dierence could be observed in the number of changes re-
garding genders.
Concerning opportunistic diseases, an increase in the 
number of tuberculosis and neurotoxoplasmosis cases 
has been reported among patients with HIV/AIDS in the 
northeastern states of Brazil10. Perhaps this is correlated 
with a predominance of cases of these diseases. Tuber-
culosis is the main cause for morbidity and mortality in 
HIV-positive patients all over the world, and is found as 
the second most frequent disease in Brazil13.
The determination of VL and CD4+ cell count  dem-
onstrated that lower viral loads account for higher CD4 
levels in treated patients, being referred as important labo-
ratory monitoring tools to investigate virologic failure in 
ART follow-up and management, including circumstanc-
es where drug changes are required4,3,8,13,14. When VL and 
CD4 measurements are not available, clinical monitoring 
will assess the patient status and determine ART change4,8. 
In the present study, VL and CD4+ recording was not 
found in every analyzed form, which does not mean that 
these data are missing, rather that they were not entered in 
the appropriate field.
Initial ART drugs (n) Drug substitutions (n and percentage)
AZT TDF ABC ddI d4T
n = 25 n = 14 (56%) n = 8 (32%) n = 2 (8%) n = 1 (4%)
EFV LPV/r ATV/r NVP ABC
n = 20 n = 10 (50%) n = 7 (35%) n = 2 (10%) n = 1 (5%)
LPV/r ATV/r EFV NVP
–
n = 19 n = 11 (57.9%0 n = 7 (36.8%) n = 1 (5.3%)
ABC AZT TDF ddI
–
n = 5 n = 3 n = 1 (20%) n = 1 (20%)
ATV/r EFV LPV/r
– –
















n, number of regimens entered into the patients’ forms. ART, antiretroviral therapy; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; d4T, stavudine; 
ddI, didanosine; EFV, efavirenz; LPV, lopinavir; NVP, nevirapine; r, ritonavir; TDF, tenofovir.
Table 3 – Panel of drug substitutions in initial regimens of antiretroviral therapy
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In certain situations where the viral load is moni-
tored, the ART regimen changes tend to occur earlier and 
within higher CD4+ levels, compared to programs with 
no VL follow-up14. In a study conducted in India, no cor-
relation between CD4+ count and therapeutic failure was 
observed, as failures occurred in patients with various 
levels of this marker15.
The antiretroviral therapy guidelines for adults in-
fected by HIV3 are periodically revised and, at times, 
changed. However, as this study database was from the 
year 2008, results were assessed based on the references 
from that year.
Most initial regimens consisted of two NRTIs + one 
NNRTI, followed by regimens with two NRTIs + one PI/r, 
with AZT + 3TC + EFV and AZT + 3TC + LPV/r being 
the predominant combinations in each case, respectively, 
in accordance with the Brazilian consensus on ART3 and 
the findings of the Caribbean and Latin-American study12. 
However, in a study conducted in Africa, South America 
and Asia, the stavudine (d4T) regimen was also quite prev-
alent14. Other regimens with three NRTIs were found in a 
low ratio, similarly to that found in a study conducted in 
23 countries16. In the present study, 3TC was the most used 
drug in initial regimens, as well as the drug with the lowest 
number of substitutions, in accordance with the results re-
ported from the Caribbean and Latin-America12. AZT was 
the drug with the highest number of substitutions.
No significant association between drug changes and 
the variables  “gender” and “age” was observed. However, 
results expressively indicated the report of ADR occur-
rence as the main reason for ART change requests, in ac-
cordance with studies conducted in Switzerland and South 
Africa17, and in the Caribbean and Latin-America12. The 
treatment of opportunistic diseases occurring simultane-
ously with ART in AIDS patients likely aects antiretrovi-
ral tolerance, increasing the toxicity risk12.
Following the results reported, AZT, the drug with the 
highest change percentage, was indicated as causing ane-
mia in many patients. Accordingly, the study in the Ca-
ribbean and Latin America revealed anemia cases in over 
70% of patients12. The guidelines on ART mention this he-
matologic change, as well as lipodystrophy, which is more 
common after one-year treatment3. Other considerable 
changes include LPV/r, which, in first regimens, was the 
most substituted drug regarding gastrointestinal reactions, 
and EFV, related to hypersensitivity reaction reports, con-
firming data already reported in the literature18.
In most cases of initial ART changes, only one drug in 
the regimen was changed, in contrast with the findings of 
the study conducted in Africa, South America, and Asia, 
in which most changes (54.9%) involved two NRTIs and 
occurred due to toxicity in 10% of patients, and therapeu-
tic failure in 74%14.
In regimens where AZT was the reason for a change 
request, TDF was the main drug chosen, followed by ABC, 
didanosine (ddI), and d4T. In the case of EFV, it was most 
often replaced by LPV/r, followed by ATV/r. Such changes 
were in accordance with the consensus recommendations 
endorsed for antiretroviral therapy3.
The number of approvals of the proposed regimens in 
the change forms was high, indicating that they were in 
accordance with the recommendations of the Brazilian 
consensus on ART3. Forms that were not initially approved 
received suggestions from CITA physicians, and these sug-
gestions were followed by the attending physicians who re-
quested the changes. It is also noteworthy that a number 
of forms were not appropriately filled and information re-
quested was missing. However, generally speaking, despite 
these limitations, this context denotes the hospital’s control 
in the management of ART, having an active committee 
with rules and regulations aiming at quality, efficacy, and 
safety of the treatments proposed to HIV-positive patients.
CONCLUSION
The main factor determining the initial ART change in the 
first year of treatment was the occurrence of adverse re-
actions, with AZT and LPV/r being the most implicated 
drugs, and anemia and gastrointestinal reactions, respec-
tively, the most often reported events.
The majority of patients had only one change in the 
initial ART over the first year of treatment. These changes 
were in accordance with the Brazilian consensus. In this 
regard, the presence of CITA members in the reference 
center contributed to better management and control of 
specific drug therapy.
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